At the beginning of 2018, the Group welcomed the good news. On 18th January, “New Values Discovery of Hong Kong Listing Company Summit Forum with 2017 Golden HK Stock” Award Ceremony was grandly held in Shenzhen Great China Hilton Hotel. With excellent brand influence and solid performance in pharmaceutical industry, CMS was awarded “2017 Golden HK Stock – the Most Valuable Pharmaceutical listing Company”. This is the second time that the Group wins the honor after receiving the 2016 “Golden Hong Kong Stock” award.
2017 Golden HK Stock award was sponsored by ZhiTongCaiJing and Royal Flush Finance, co-sponsored by XueQiu, and fully supported by HKEx and Chinese Securities Association of Hong Kong (CSAHK). The Expert Review Panel is consisted of Hong Kong top nine Chinese funded brokers. After evaluating and rating the following aspects of involved companies: performance of the past year, industry ranking, corporate governance, business model, market influence and performance in capital market, winners was finally selected for honoring those Hong Kong listed companies with top investment value and growth potential.
“2017 Golden HK Stock- the Most Valuable Pharmaceutical Listing Company” is for honoring the fastest-growing Hong Kong listed pharmaceutical companies with high-profile in capital market and great growth potential. Winning this honor for the second time, fully reflects the recognition and expectation from the capital market for the Group’s performance and growth potential, which significantly inspires and incents CMS. In the future, with sensitive market responding and rich practical experiences, the Group will continue to search and introduce high quality products with innovation and high academic value from the global market with diversified directions. And through china-wide covered professional academic promotional network, delivering the medical evidence and advance information of the products, to create value for clients and taking responsibility for society constantly.
